Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT ID: NCT07335341

Last Updated: 2026-01-20

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2026-04-30

Brief Summary

The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Detailed Description

The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.

Conditions

Venous Embolism of Lower Extremities (Diagnosis); Arterial Embolism and Thrombosis; Acute DVT of Lower Extremity; Chronic DVT of Lower Extremity; DVT; Deep Vein Thrombosis Leg; Thrombus in the Peripheral Venous Vasculature; Peripheral Arterial Disease; Acute Limb Ischemia; Lower Extremity Acute Limb Ischemia; LE ALI

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

Liberant Thrombectomy System

The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:

1. Patient treated is age ≥ 22 years at the time of procedure

2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Endovascular

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John R Laird Jr, MD

Role: PRINCIPAL_INVESTIGATOR

Medtronic Endovascular

Central Contacts

Manasa Gudipally

Role: CONTACT

manasa.gudipally@medtronic.com

763-514-4000

Janki Shah

Role: CONTACT

janki.shah@medtronic.com

Other Identifiers

MDT25034

Identifier Type: -

Identifier Source: org_study_id